United Asset Strategies Inc. Buys 17,412 Shares of Edwards Lifesciences Corporation $EW

Key Points

• United Asset Strategies Inc. has increased its holdings in Edwards Lifesciences Corporation by 10.4%, owning a total of 185,571 shares valued at approximately $13.45 million.
• Institutional investors control 79.46% of Edwards Lifesciences' stocks, with notable increases from other hedge funds such as Jennison Associates LLC, which raised its position by 34.3%.
• Edwards Lifesciences reported earnings of $0.67 per share for the most recent quarter, surpassing expectations and projecting future EPS guidance of 2.400-2.500 for FY 2025.

United Asset Strategies Inc. boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 10.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 185,571 shares of the medical research company's stock after purchasing an additional 17,412 shares during the quarter. Edwards Lifesciences comprises 1.2% of United Asset Strategies Inc.'s portfolio, making the stock its 26th biggest holding. United Asset Strategies Inc.'s holdings in Edwards Lifesciences were worth $13,450,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jennison Associates LLC grew its holdings in Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after buying an additional 2,576,383 shares in the last quarter. Brown Advisory Inc. grew its holdings in Edwards Lifesciences by 7.6% during the 4th quarter. Brown Advisory Inc. now owns 8,155,355 shares of the medical research company's stock valued at $603,741,000 after buying an additional 575,699 shares in the last quarter. Deutsche Bank AG grew its holdings in Edwards Lifesciences by 10.4% during the 4th quarter. Deutsche Bank AG now owns 6,903,202 shares of the medical research company's stock valued at $511,044,000 after buying an additional 652,923 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Edwards Lifesciences by 8.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,519,257 shares of the medical research company's stock valued at $482,621,000 after buying an additional 513,468 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Edwards Lifesciences by 21.8% during the 4th quarter. Northern Trust Corp now owns 6,505,227 shares of the medical research company's stock valued at $481,582,000 after buying an additional 1,165,845 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on EW. Daiwa America upgraded Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 29th. Royal Bank Of Canada raised their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Evercore ISI raised their price target on Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a report on Friday, July 25th. Stifel Nicolaus raised their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a "buy" rating in a report on Friday, July 25th. Finally, Truist Financial raised their price target on Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $85.90.

Edwards Lifesciences Trading Up 0.1%

Shares of EW stock traded up $0.06 on Tuesday, reaching $80.92. 843,234 shares of the company's stock were exchanged, compared to its average volume of 4,495,265. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $47.51 billion, a PE ratio of 11.65, a P/E/G ratio of 3.95 and a beta of 1.08. The company's fifty day simple moving average is $77.71 and its 200 day simple moving average is $74.79.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the company earned $0.70 EPS. Edwards Lifesciences's quarterly revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 2,570 shares of Edwards Lifesciences stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total transaction of $198,918.00. Following the completion of the sale, the vice president directly owned 50,356 shares of the company's stock, valued at $3,897,554.40. The trade was a 4.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,584 shares of company stock valued at $1,897,762 in the last ninety days. Corporate insiders own 0.34% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.